| scholarly article | Q13442814 |
| P5530 | Altmetric DOI | 10.1016/S1470-2045(17)30043-8 |
| P6409 | CORE ID | 153353730 |
| P6179 | Dimensions Publication ID | 1083527635 |
| P356 | DOI | 10.1016/S1470-2045(17)30043-8 |
| P953 | full work available at URL | http://eprints.whiterose.ac.uk/111465/ |
| P932 | PMC publication ID | 5337626 |
| P698 | PubMed publication ID | 28163000 |
| P1154 | Scopus EID | 2-s2.0-85011388691 |
| P50 | author | Michael Griffin | Q67954767 |
| Elizabeth C Smyth | Q82087786 | ||
| Alicia Okines | Q88835488 | ||
| David Cunningham | Q38803238 | ||
| Jane M. Blazeby | Q40019561 | ||
| P2093 | author name string | Laura Stevenson | |
| William H Allum | |||
| Derek Alderson | |||
| Wasat Mansoor | |||
| Sally P Stenning | |||
| Heike I Grabsch | |||
| Ruth E Langley | |||
| Thomas Crosby | |||
| Fareeda Y Coxon | |||
| Stephen J Falk | |||
| Sam Rowley | |||
| Suzanne Darby | |||
| Kate A Sumpter | |||
| P2860 | cites work | Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial. | Q43967231 |
| Phase II study of preoperative concurrent chemoradiotherapy with S-1 plus bevacizumab for locally advanced resectable rectal adenocarcinoma | Q44539823 | ||
| Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial | Q47815963 | ||
| Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report | Q61867831 | ||
| Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer | Q80807888 | ||
| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
| No adjustments are needed for multiple comparisons | Q28292261 | ||
| Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer | Q29619394 | ||
| Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study | Q29620647 | ||
| Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial | Q29620687 | ||
| Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial | Q29620917 | ||
| Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40 | Q33416887 | ||
| Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial | Q34627996 | ||
| Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08 | Q34662825 | ||
| Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma | Q35034753 | ||
| Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). | Q35981433 | ||
| Bevacizumab added to neoadjuvant chemotherapy for breast cancer | Q36106083 | ||
| Neoadjuvant Therapy of DOF Regimen Plus Bevacizumab Can Increase Surgical Resection Ratein Locally Advanced Gastric Cancer: A Randomized, Controlled Study | Q36207040 | ||
| Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation | Q36299062 | ||
| Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cance | Q36750960 | ||
| Pathological response and safety of two neoadjuvant strategies with bevacizumab in MRI-defined locally advanced T3 resectable rectal cancer: a randomized, noncomparative phase II study | Q38425364 | ||
| Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial | Q38443954 | ||
| Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial | Q41069109 | ||
| Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial | Q42677492 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | adenocarcinoma | Q356033 |
| bevacizumab | Q413299 | ||
| multicenter clinical trial | Q6934595 | ||
| chemotherapy | Q974135 | ||
| phase III clinical trial | Q42824827 | ||
| phase II clinical trial | Q42824440 | ||
| P304 | page(s) | 357-370 | |
| P577 | publication date | 2017-02-03 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial | |
| P478 | volume | 18 |
| Q58547850 | A systematic review and meta-analysis on the effect of angiogenesis blockade for the treatment of gastric cancer |
| Q100490607 | Advances in targeted therapy for esophageal cancer |
| Q47218543 | Angiogenesis and Anti-Angiogenic Therapy in Gastric Cancer |
| Q54465350 | Anti-angiogenesis: disappointment in localised oesophagogastric cancer. |
| Q58737369 | Between evidence and new perspectives on the current state of the multimodal approach to gastric cancer: Is there still a role for radiation therapy? |
| Q92557676 | COMplot, A Graphical Presentation of Complication Profiles and Adverse Effects for the Curative Treatment of Gastric Cancer: A Systematic Review and Meta-Analysis |
| Q58755544 | CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in re |
| Q88344849 | Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial |
| Q89687522 | Clinical significance of various growth factors in patients with different gastric neoplasms |
| Q91588983 | Controversies in preoperative therapy in esophageal cancer: Current evidence and ongoing research |
| Q90319007 | Current status of adjuvant chemotherapy for gastric cancer |
| Q55033047 | Customization of therapy for gastroesophageal adenocarcinoma patients. |
| Q55117181 | Distinct molecular subtypes of gastric cancer: from Laurén to molecular pathology. |
| Q42378852 | Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study |
| Q88316184 | Histopathological regression after taxane based neoadjuvant chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma |
| Q89739906 | Impact of postoperative complications on survival after oesophagectomy for oesophageal cancer |
| Q92324369 | Intraoperative intraperitoneal chemotherapy increases the incidence of anastomotic leakage after anterior resection of rectal tumors |
| Q93064544 | Multimodal Treatment Strategies in Esophagogastric Junction Cancer: a Western Perspective |
| Q89272213 | Multimodal treatment in locally advanced gastric cancer |
| Q64087363 | Multimodal treatments for resectable esophagogastric junction cancer: a systematic review and network meta-analysis |
| Q89992803 | Neoadjuvant therapy for esophageal cancer: Who, when, and what? |
| Q88119081 | No benefit from ramucirumab in first-line chemotherapy? |
| Q91338862 | No clear role for angiogenesis inhibitors in first-line therapy for stomach cancer |
| Q92384079 | Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer |
| Q93024218 | Optimal management of gastroesophageal junction cancer |
| Q95521380 | Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma |
| Q88042473 | Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma |
| Q88042477 | Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma - Authors' reply |
| Q38645728 | Perioperative Therapy of Oesophagogastric Adenocarcinoma: Mainstay and Future Directions. |
| Q64064533 | Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions |
| Q92586715 | Perioperative chemotherapy for gastric cancer in FLOT4 |
| Q92586722 | Perioperative chemotherapy for gastric cancer in FLOT4 - Authors' reply |
| Q93080677 | Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4) |
| Q64912272 | Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis. |
| Q94602735 | Ramucirumab plus paclitaxel or FOLFIRI in platinum-refractory advanced or metastatic gastric or gastroesophageal junction adenocarcinoma-experience at two centres |
| Q55658098 | Recent advancements in esophageal cancer treatment in Japan. |
| Q64912862 | Recent advances in the management of gastric adenocarcinoma patients. |
| Q55690221 | Refining the management of resectable esophagogastric cancer: FLOT4, CRITICS, OE05, MAGIC-B and the promise of molecular classification. |
| Q58729601 | Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials |
| Q92897463 | Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma: A Randomized Phase 2 Clinical Trial |
| Q92760885 | Safety and efficacy of a docetaxel-5FU-oxaliplatin regimen with or without trastuzumab in neoadjuvant treatment of localized gastric or gastroesophageal junction cancer: A retrospective study |
| Q64289851 | Suppression of fumarate hydratase activity increases the efficacy of cisplatin-mediated chemotherapy in gastric cancer |
| Q92260339 | Systemic inflammation score is a prognostic marker after curative resection in gastric cancer |
| Q92408693 | Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination Strategies |
| Q61795899 | The Efficacy and Safety of (Neo)Adjuvant Therapy for Gastric Cancer: A Network Meta-analysis |
| Q49970732 | The Role of Systemic Therapy in Resectable Gastric and Gastro-oesophageal Junction Cancer |
| Q55330265 | Translational research and application of basic biology to clinical trial development in GI cancers. |
| Q92060989 | Trastuzumab with FLOT Regimen for the Perioperative Treatment of Resectable HER2 + Advanced Gastric Cancer: A Retrospective Study |
| Q90319010 | Tumor progression-dependent angiogenesis in gastric cancer and its potential application |
| Q48335407 | Tumor regression grading of gastrointestinal cancers after neoadjuvant therapy |
| Q52654643 | Upper gastrointestinal malignancies in 2017: current perspectives and future approaches. |
| Q89823531 | VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study |
| Q91045576 | Varying practices in tumor regression grading of gastrointestinal carcinomas after neoadjuvant therapy: results of an international survey |
| Q90643376 | Vascular calcification does not predict anastomotic leak or conduit necrosis following oesophagectomy |
| Q91997710 | Vessel co-option in cancer |
| Q55317227 | siRNA Library Screening Identifies a Druggable Immune-Signature Driving Esophageal Adenocarcinoma Cell Growth. |
Search more.